Trial
NCT00780676
Personalized Treatment Selection for Metastatic Breast Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
Bristol-Myers Squibb; AstraZeneca
Condition
Breast Cancer
Intervention
Dasatinib
Why stopped
Closed early for futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-03